Edgewise Therapeutics’ stock soared after positive Phase 2 trial results for its Becker muscular dystrophy treatment. Other companies saw significant pre-market price changes, with some gaining substantially while others experienced sharp declines, reflecting the volatility of the market. The biotech sector and clinical trial results remain major market drivers.
Sai University in Chennai is launching four new schools in AI, management, biotechnology, and media studies, offering 16 new programs starting next year. The university will recruit international faculty and aims to provide a liberal education model, focusing on undergraduate education across arts and sciences, technology, and law.
The global single domain antibody platform market is booming, driven by increased healthcare R&D and the platforms’ efficacy in treating various diseases. This report projects market growth to US$ 86 million by 2034, with significant contributions from North America and East Asia. Leading players are driving innovation, but access to camelids, the primary source of these antibodies, remains a challenge.
The global psoriasis drug market is experiencing explosive growth, projected to reach US$27.57 billion by 2034. Driven by increasing prevalence, R&D investment, and innovative treatments, this market analysis reveals key trends, leading players, and future projections.
Century Therapeutics Inc (IPSC) experienced a significant stock price surge of 20.74% on Wednesday, reaching $1.63 per share, its highest single-day jump in over 11 months. This surge follows Casdin Capital’s acquisition of an additional 1.38 million shares, increasing their stake in the biotechnology company by 43%. The investment highlights Casdin Capital’s confidence in Century Therapeutics’ future.
Agenus Inc. (AGEN) stock surged over 16% after securing a $22 million mortgage and unveiling a strategic realignment plan focused on its promising BOT/BAL cancer therapy. The plan aims to significantly reduce cash burn and accelerate development of this key asset.
Biotech company Unnatural Products (UNP) announced the appointment of Simon Bailey, Ph.D., as its new Chief Operating Officer and President of R&D. Dr. Bailey brings over 25 years of experience in drug discovery and development to lead UNP’s growth in macrocyclic therapeutics, a promising new area of drug development.
Elicit Plant, a leader in biosolutions for broadacre crops, has raised $48 million in Series B funding to accelerate its global expansion, particularly in the U.S. Corn Belt. The company’s phytosterol-based biosolutions offer farmers a sustainable way to reduce crop water use by 20%, addressing the growing challenge of water stress across the globe.
Lineage Cell Therapeutics (LCTX) is set to release its quarterly earnings on Thursday, November 14th. Analysts predict a loss per share of $0.04, but investors will be looking for positive guidance and an indication of the company’s future trajectory. This article provides a comprehensive analysis of Lineage Cell Therapeutics’s past performance, market sentiment, and key financial metrics, offering insights into what investors can expect from the upcoming earnings announcement.
Inovio Pharmaceuticals is set to release its quarterly earnings on November 14th, 2024. Analysts anticipate a loss per share, but investors are hoping for positive guidance and a potential surge in share price. This article analyzes historical performance, analyst sentiment, and key financial metrics to provide insights for investors ahead of the earnings announcement.
